Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients

Chung, Byung Ha; Kim, Kyoung Woon; Sun, In O; Choi, Sun Ryoung; Park, Hoon Suk; Jeon, Eun Joo; Kim, Bomi; Choi, Bum Soon; Park, Cheol Whee; Kim, Yong Soo; Cho, Mi‐La; Yang, Chul Woo

doi:10.1016/j.imlet.2011.10.002

Cited by 45 publications

(50 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, the incidence of cognitive impairment was 45.1%, which was significantly lower than that of elderly patients with CRF, but our findings are in agreement with those of Witko-Sarsat [4] and Weiner [17]. The age, duration of illness, creatinine, urea nitrogen and haemoglobin levels and creatinine clearance were significantly different in patients with both CRF and cognitive impairment than in the CRF group with normal cognitive function.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Change of Peripheral Blood Treg/Thl7 in Cognitive Impairment with Chronic Renal Failure Patients

Wang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: To investigate the changes in peripheral blood Treg/Th17 cell balance and its significance in patients with chronic renal failure (CRF) and cognitive impairment. Methods: A total of 71 patients with CRF were enrolled as a study group. The patients were divided into a cognitive impairment group and a normal cognitive function group according to the Mini-Mental State Examination (MMSE). Peripheral blood Treg and Th17 cells were analyzed by flow cytometry and their relevant cytokines (IL-17, IL-10 and TGF-β) and other biochemical indicators, including C-reactive protein (CRP) and IL-6, were determined by ELISA. Results: Thepatients with both CRF and cognitive impairment were older than the cognitive normal groups. Peripheral blood Treg cells by Flow cytometry (the CRF cognitive impairment group 5.57±1.3%, CRF group with normal cognitive function 7.5 ± 0.9% and normal control group 9.7 ± 1.7%,P<0.05) and its related cytokines (IL-10 and TGF-β) by ELISA detection were lower in the group with cognitive impairment than in the group without cognitive impairment ( IL-10, 7.4±4.2 pg/mL, 13.8±3.9 pg/mL, 18.3±3.2 pg/mL; TGF-β 335.6±175.3 pg/mL, 512.7 ± 114.6 pg/mL, 953.8±373.4 pg/mL P < 0.05, respectively).However, Th17 cell numbers (the CRF cognitive impairment group 3.3 ± 0.7%, CRF group with normal cognitive function2.2 ± 0.5% and normal control group 1.5 ± 0.3%),and cytokine levels (IL-17, IL-6 and CRP) were higher in the group with cognitive impairment IL-6 (21.3 ± 5.1 pg/mL), IL-17 (18.5 ± 4.2 pg/mL) and CRP (20.3 ± 5.9 mg/L) in the CRF group with cognitive impairment when compared with the CRF group and normal cognitive function (12.2 ± 4.5 pg/mL, 12.1 ± 3.7 pg/mL and 13.5 ± 4.6 mg/L, respectively) or the normal control group (9.2 ± 5.8 pg/mL, 7.4 ± 2.6 pg/mL and 3.2 ± 1.3 mg/L, respectively, P<0.05). The frequencies of Treg in patients with CRF were positively correlated with the MMSE scores ((r = 0.518, P < 0.05), but the Th17 numbers were negatively correlated (r = -0.435, P < 0.05). Conclusion: An imbalance of peripheral blood Treg/Th17 cells is associated with cognitive impairment in patients with CRF.

show abstract

Section: Discussionsupporting

confidence: 91%

“…In-depth immunological research has revealed new T cell subsets, such as Th9, Th17, Th22, Tfh and Treg [17]. Regulation of the balance between these T cell subsets and the production of a moderate immune response are conducive to maintaining the body’s immune home-ostasis and tolerance.…”

Section: Discussionmentioning

confidence: 99%

Change of Peripheral Blood Treg/Thl7 in Cognitive Impairment with Chronic Renal Failure Patients

Wang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Serum IL 17 level in hypertension patients is much higher than that in normal individuals, and IL 17 concentration is positively correlated with blood pressure values. Interestingly, Chung et al 11 found that hemodialysis patients had an evidently increased IL 17 level, compared to healthy people in the control group, and IL17 could not be removed from the body by hemodialysis. Therefore, IL 17 could play a role in the causation of refractory hypertension in hemodialysis.…”

Section: Introductionmentioning

confidence: 99%

Association of interleukin 17 / angiotensin II with refractory hypertension risk in hemodialysis patients

et al. 2016

View full text Add to dashboard Cite

Objective: The study was performed to investigate the association of interleukin 17 (IL 17) or angiotensin II (Ang II) with refractory hypertension risk in hemodialysis patients. Methods: Ninety hemodialysis patients were enrolled into this study, and those with hypertension were divided into two groups. The Easy-to-Control Hypertension group (ECHG) had fifty patients, while the refractory hypertension group (RHG) had forty patients. Twenty healthy individuals were recruited as the control group. IL17 and Ang II were determined using a human IL 17 / Ang II enzyme-linked immunosorbent assay kit. Serum IL 17 and Ang II concentrations in RHG patients were higher than those in ECHG patients. Results: Serum IL 17 and Ang II concentrations in both patient groups were higher than those in the control group. Linear regression analysis showed a positive correlation between IL 17 and Ang II. In multivariate regression analysis, we found that IL17 and Ang II were associated with refractory hypertension risk in hemodialysis patients. Conclusion: IL17 and Ang II were associated with refractory hypertension risk in hemodialysis patients. There was also a positive correlation between IL 17and Ang II.

show abstract

“…Clinical demonstrations of immune defects characterized by increasing immune responses to T cellrelated antigens were observed in CRF patients [3]. Recent studies have demonstrated that the percentage of T helper (Th) 17 cells was significantly higher, while the percentage of regulatory T cells (Treg) was significantly decreased in patients with renal disease [4,5]. Although studies have raised the possibility that Th17 and Treg cells regulate immune activation in CRF, further research on the underlying mechanism and drug interfere has not been conducted.…”

Section: Introductionmentioning

confidence: 99%

Citrate Attenuates Adenine-Induced Chronic Renal Failure in Rats by Modulating the Th17/Treg Cell Balance

Zhu

et al. 2015

Inflammation

View full text Add to dashboard Cite

Citrate is commonly used as an anticoagulant in hemodialysis for chronic renal failure (CRF) and for the regulation of the immune dysfunction in CRF patients. The objective of this study was to investigate the effect of citrate on the balance of T helper 17 (Th17) and regulatory T (Treg) cells in CRF. The levels of blood urea nitrogen (BUN) and serum creatinine (Scr) were significantly increased in the CRF model group compared to the control group, and were decreased in the citrate-treated groups. Citrate treatment inhibited the viability of Th17 cells while elevating the viability of Treg cells in CRF rats. Moreover, Th17-related cytokines significantly decreased while the Treg-related cytokines significantly increased with citrate treatment. Moreover, citrate had a negative influence on the deviation of Th17/Treg cells in CRF rats. Therefore, our study suggests that citrate had an anti-inflammatory effect on CRF through the modulation of the Th17/Treg balance.

show abstract

Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients

Cited by 45 publications

References 37 publications

Change of Peripheral Blood Treg/Thl7 in Cognitive Impairment with Chronic Renal Failure Patients

Change of Peripheral Blood Treg/Thl7 in Cognitive Impairment with Chronic Renal Failure Patients

Association of interleukin 17 / angiotensin II with refractory hypertension risk in hemodialysis patients

Citrate Attenuates Adenine-Induced Chronic Renal Failure in Rats by Modulating the Th17/Treg Cell Balance

Contact Info

Product

Resources

About